Rong Tao
Clinical trials sponsored by Rong Tao, explained in plain language.
-
Immunotherapy combo may outperform chemo in rare lymphoma
Disease control Recruiting nowThis Phase 3 trial tests whether an immunotherapy-based regimen (sintilimab, pegaspargase, and anlotinib) works better than standard chemotherapy before a stem cell transplant in people with newly diagnosed, advanced extranodal NK/T-cell lymphoma. Participants are randomly assign…
Phase: PHASE3 • Sponsor: Rong Tao • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New combo attack on rare blood cancer shows promise in early trial
Disease control Recruiting nowThis study tests two drugs, tislelizumab and zeprumetostat, together in people with a rare type of lymphoma that has come back or not responded to treatment. About 107 adults will take part to see if the combination is safe and shrinks tumors. The goal is to control the cancer, n…
Phase: PHASE1, PHASE2 • Sponsor: Rong Tao • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New pill aims to wipe out lingering lymphoma cells after remission
Disease control Recruiting nowThis phase 2 trial tests a drug called chidamide in people with a type of aggressive lymphoma (double-expressor DLBCL) who are in remission but still have traces of cancer DNA in their blood. The goal is to see if taking chidamide pills for up to two years can clear those hidden …
Phase: PHASE2 • Sponsor: Rong Tao • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Can tracking thousands of patients unlock the secrets of rare EBV-driven blood cancers?
Knowledge-focused Recruiting nowThis study follows 1,500 people with Epstein-Barr virus-positive T/NK-cell lymphoproliferative diseases — rare conditions where the virus drives abnormal immune cell growth. Researchers will collect medical history, treatment details, and blood samples to see how the diseases beh…
Sponsor: Rong Tao • Aim: Knowledge-focused
Last updated Aug 15, 2026 00:00 UTC